These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22721884)

  • 1. Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
    Zavala JA; Munhoz RP; Teive HA
    J Clin Neurosci; 2012 Sep; 19(9):1298-9. PubMed ID: 22721884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole.
    Cicero CE; Nicoletti A; Mostile G; Zappia M
    Postgrad Med J; 2016 Aug; 92(1090):484. PubMed ID: 26941267
    [No Abstract]   [Full Text] [Related]  

  • 3. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pramipexole on the onset of levodopa-related dyskinesias.
    Constantinescu R; Romer M; McDermott MP; Kamp C; Kieburtz K;
    Mov Disord; 2007 Jul; 22(9):1317-9. PubMed ID: 17534955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Severe leg edema associated with the use of dopaminergic drugs in Parkinson's disease. Report of one case].
    Miranda C M; Hudson A L
    Rev Med Chil; 2017 Dec; 145(12):1624-1625. PubMed ID: 29652961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson's disease.
    Katz KA; Cotsarelis G; Gupta R; Seykora JT
    J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S103-4. PubMed ID: 17052518
    [No Abstract]   [Full Text] [Related]  

  • 9. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dilemma in Parkinson's Treatment; Levodopa Monotherapy May be the Best Choice.
    Abbasi MH; Esmaeili S; Habibi SA; Shahidi GA
    J Clin Neurosci; 2020 Sep; 79():219-223. PubMed ID: 33070900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoophilia and Parkinson's disease.
    Almeida KJ; de Oliveira Filho MC; Lopes Nery PC; Guimarães Silva JS; Campos Sousa RN
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1167-8. PubMed ID: 23973014
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk factors for the development of pedal edema in patients using pramipexole.
    Kleiner-Fisman G; Fisman DN
    Arch Neurol; 2007 Jun; 64(6):820-4. PubMed ID: 17420306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
    Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole-induced obsessive-compulsive symptoms in a patient with Parkinson's disease and disgust sensitivity.
    Gopalan P; Azzam PN; Hudak R
    Psychosomatics; 2013; 54(3):286-9. PubMed ID: 23218062
    [No Abstract]   [Full Text] [Related]  

  • 18. Current and future approaches to therapy.
    Birkmayer W; Birkmayer JD
    Adv Neurol; 1987; 45():511-2. PubMed ID: 3103393
    [No Abstract]   [Full Text] [Related]  

  • 19. Reversible antecollis associated with pramipexole in a patient with Parkinson's disease.
    Kim HJ; Jeon BS; Kim SH; Han SH
    J Clin Neurosci; 2012 Jun; 19(6):903-4. PubMed ID: 22353251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramipexole and gender identity disorder: expanding the phenotype of hypersexuality in Parkinson's disease.
    Odiyoor M; Kobylecki C; Hackett RJ; Silverdale MA; Kellett MW
    Mov Disord; 2009 Dec; 24(16):2434-5. PubMed ID: 19891000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.